Recently, combination therapies of Ang2 inhibition and cytotoxic drugs with agents targeting tyrosine kinases or VEGF-A have shown enhanced anti-tumor effects compared with monotherapy [56]. This evidence concerns the gene VEGFA and neoplasm.